Physician profile
Kenneth E Bresky
NPI 1255368452
$34,064.13
in general payments reported to CMS, 2019-2025
40 companies · $4,766 in 2025
The $4,766 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,272 · 2020: $3,448 · 2021: $5,191 · 2022: $4,856 · 2023: $5,499 · 2024: $5,033 · 2025: $4,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,238 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,950.07 |
| Consulting Fee | $1,237.50 |
| Education | $110.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,304.00 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $4,709.69 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $4,342.82 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,859.96 | 2019-2025 | |
| Ucb, INC. | $2,764.67 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $2,163.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,105.48 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,059.78 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,023.40 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $951.41 | 2020-2025 | Acthar |
| Radius Health, INC. | $904.65 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $778.32 | 2019-2024 | Taltz |
| Genzyme Corporation | $594.36 | 2021-2024 | |
| Mallinckrodt Enterprises LLC | $561.33 | 2019 | |
| Horizon Therapeutics Plc | $455.06 | 2019-2023 | Krystexxa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Bresky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.